Professor Chen Mingyuan, former vice president of the Sun Yat-sen University Nanchang Hospital, deputy director of the Department of Nasopharyngeal Carcinoma of Sun Yat-sen University Cancer Center, director of the Surgical Center of Nasopharyngeal Carcinoma of Sun Yat-sen University Cancer Center, director of Sun Yat-sen University Cancer Center-The Fifth Affiliated Hospital of Guangzhou Medical University Nasopharyngeal Cancer Surgery Cooperative Ward. He enjoys the honor of National Technology Innovation Leading Talents, New Century Excellent Talents, Outstanding Young Medical Talents in Guangdong Province, etc. He also obtains the title to be the first head-and-neck oncologist in mainland China to be invited to launch courses in American Academy of Otolaryngology-Head and Neck Surgery. His research interest focuses on comprehensive treatment and molecular mechanism of nasopharyngeal carcinoma(NPC). As for recurrent NPC, he pioneered the surgical technique of minimally invasive surgery with transnasal endoscopy, providing a new, safe and effective therapeutic pattern for it. The surgery was also promoted to the treatment of nasopharyngeal necrosis and newly-diagnosed stage I NPC. With respect to metastatic nasopharyngeal carcinoma, he led a number of large-scale phase III clinical trials, established sequential chemoradiotherapy with neoadjuvant chemotherapy as the optimal treatment mode for the prevention and treatment of distant metastasis of NPC, which was successfully selected as one of the 17 major advances in 2021 by ASCO. He also found a number of new and efficient biomarkers, which can help screen accurately and conduct individualized treatments for patients with high risk of recurrence and metastasis.